29 Jun, 2026
Tinuviel Therapeutics Partners with Kipu Quantum to Combat Drug-Resistant Infections
Tinuviel Therapeutics and Kipu Quantum are applying quantum-enhanced computational methods to model complex microbial ecosystems and identify new strategies for treating drug-resistant infections.
Read More
29 Jun, 2026
Tinuviel Therapeutics Partners with Kipu Quantum to Combat Drug-Resistant Infections
Tinuviel Therapeutics and Kipu Quantum are applying quantum-enhanced computational methods to model complex microbial ecosystems and identify new strategies for treating drug-resistant infections.
22 Jun, 2026
Tinuviel Therapeutics Announces Collaboration with Hudson Institute of Medical Research
Tinuviel Therapeutics and Hudson Institute of Medical Research are combining experimental microbiome science with AI-powered digital-twin modeling to predict microbiome resilience and accelerate precision diagnostics and therapeutics.
15 Jun, 2026
Tinuviel Therapeutics is Selected for the Wellcome Leap FORM Program
Supported by Wellcome Leap's $50M FORM program, Tinuviel Therapeutics is combining AI, systems biology, and microbiome science to build predictive tools for early-life health and next-generation therapeutics.
24 Apr, 2026
Tinuviel Therapeutics Announces Collaboration with JIJ to Advance Predictive Microbiome Modeling
Tinuviel Therapeutics and JIJ are partnering to integrate mathematical optimization, advanced computing, and digital-twin modeling, moving microbiome research from description to prediction.